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Background: It has been reported that rousvastatin improved atherosclerosis in carotid artery in terms of intimal media thickness 
measured with ultrasound, however, its substantial effect on endothelial dysfunction by rosuvastatin is still unclear.
methods and results: The 47 patients with coronary artery disease (CAD), aged 70.2±9.5 years (mean±SD) (35 males), were assigned 
to receive an aggressive lipid lowering treatment with rosuvastatin for 24 weeks. Rosuvastatin at 2.5 mg was initially administrated for 
total patients, among which 10 patients were naïve and 37 patients were switched from other statin to 5mg rosuvastatin. The dosage 
of rosuvastatin was titrated up to 20mg until LDL-C level became below 80mg/dl. Endothelial function was assessed by the reactive 
hyperemia of peripheral arterial tonometry index (RHI) in radial artery by EndPAT 2000. After treatment, RHI levels significantly improved 
from 1.60±0.31 to 1.77±0.57(p=0.04) (+12.8±36.9%). In lipid profile, LDL-Cholesterol decreased from 112.6±23.3 to 85.5±20.2 mg/dl, 
(p<0.001). However, HDL-Cholesterol (50.9±14.5 to 51.7±14.5 mg/dl, p=0.52) and Hs-CRP(0.19±0.46 to 0.12±0.21 mg/dl, p=0.23) were not 
changed significantly after treatment.
Conclusion:  Rosuvastatin significantly improved RHI in patients with coronary artery disease although 79% of patients had a different 
statin previously. Aggressive LDL-C level reduction by rosuvastatin might improve endothelial function even without improvement in HDL-C 
and Hs-CRP level.
